{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:21:28Z","timestamp":1762899688099,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:00:00Z","timestamp":1547769600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Inform Decis Mak"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12911-019-0743-x","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T09:04:01Z","timestamp":1547802241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing"],"prefix":"10.1186","volume":"19","author":[{"given":"Grace K.","family":"Dy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary K.","family":"Nesline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonios","family":"Papanicolau-Sengos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"DePietro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles M.","family":"LeVea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Early","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Grand\u2019Maison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Boland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc S.","family":"Ernstoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Edge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey","family":"Akers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateusz","family":"Opyrchal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurkamal","family":"Chatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunle","family":"Odunsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarabjot","family":"Pabla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Conroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean T.","family":"Glenn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanchun T.","family":"DeFedericis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blake","family":"Burgher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Andreas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Giamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maochun","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yirong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Kanehira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicia L.","family":"Lenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Frederick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashikant","family":"Lele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Galluzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Kuvshinoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3441-8363","authenticated-orcid":false,"given":"Carl","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,18]]},"reference":[{"key":"743_CR1","unstructured":"U.S. Food and Drug Administration. CDRH\u2019S APPROACH TO TUMOR PROFILING NEXT GENERATION SEQUENCING TESTS. Silver Spring, MD: U.S. Food and Drug Administration; 2017. \n                    https:\/\/www.fda.gov\/downloads\/MedicalDevices\/ProductsandMedicalProcedures\/InVitroDiagnostics\/UCM584603.pdf\n                    \n                  ."},{"key":"743_CR2","doi-asserted-by":"publisher","unstructured":"FDA. EVALUATION OF AUTOMATIC CLASS III DESIGNATION FOR MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets). 2017;:1\u201357. doi:\n                    https:\/\/doi.org\/10.1164\/rccm.201205-0815OC\n                    \n                  .","DOI":"10.1164\/rccm.201205-0815OC"},{"key":"743_CR3","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","volume":"18","author":"A-M Tsimberidou","year":"2012","unstructured":"Tsimberidou A-M, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012;18:6373\u201383. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1627\n                    \n                  .","journal-title":"Clin Cancer Res"},{"key":"743_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-016-0364-2","volume":"8","author":"TL Stockley","year":"2016","unstructured":"Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, et al. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT\/COMPACT trial. Genome Med. 2016;8:109. \n                    https:\/\/doi.org\/10.1186\/s13073-016-0364-2\n                    \n                  .","journal-title":"Genome Med"},{"key":"743_CR5","doi-asserted-by":"publisher","first-page":"41806","DOI":"10.18632\/oncotarget.16018","volume":"8","author":"NP Arango","year":"2017","unstructured":"Arango NP, Brusco L, Shaw KRM, Chen K, Eterovic AK, Holla V, et al. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget. 2017;8:41806\u201314. \n                    https:\/\/doi.org\/10.18632\/oncotarget.16018\n                    \n                  .","journal-title":"Oncotarget"},{"key":"743_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3587-8","volume":"17","author":"T Hilal","year":"2017","unstructured":"Hilal T, Nakazawa M, Hodskins J, Villano JL, Mathew A, Goel G, et al. Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy. BMC Cancer. 2017;17:602. \n                    https:\/\/doi.org\/10.1186\/s12885-017-3587-8\n                    \n                  .","journal-title":"BMC Cancer"},{"key":"743_CR7","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1158\/2159-8290.CD-16-1337","volume":"7","author":"EJ Jordan","year":"2017","unstructured":"Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 2017;7:596\u2013609. \n                    https:\/\/doi.org\/10.1158\/2159-8290.CD-16-1337\n                    \n                  .","journal-title":"Cancer Discov"},{"key":"743_CR8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jmoldx.2016.10.008","volume":"19","author":"AN Sireci","year":"2017","unstructured":"Sireci AN, Aggarwal VS, Turk AT, Gindin T, Mansukhani MM, Hsiao SJ. Clinical genomic profiling of a diverse Array of oncology specimens at a large academic Cancer center. J Mol Diagnostics. 2017;19:277\u201387. \n                    https:\/\/doi.org\/10.1016\/j.jmoldx.2016.10.008\n                    \n                  .","journal-title":"J Mol Diagnostics"},{"key":"743_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00002","volume":"2017","author":"A-M Tsimberidou","year":"2017","unstructured":"Tsimberidou A-M, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, et al. Initiative for molecular profiling and advanced Cancer therapy (IMPACT): an MD Anderson precision medicine study. JCO Precis Oncol. 2017;2017:1\u201318. \n                    https:\/\/doi.org\/10.1200\/PO.17.00002\n                    \n                  .","journal-title":"JCO Precis Oncol"},{"key":"743_CR10","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1093\/annonc\/mdx294","volume":"28","author":"AM Schram","year":"2017","unstructured":"Schram AM, Reales D, Galle J, Cambria R, Durany R, Feldman D, et al. Oncologist use and perception of large panel next-generation tumor sequencing. Ann Oncol. 2017;28:2298\u2013304. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx294\n                    \n                  .","journal-title":"Ann Oncol"},{"key":"743_CR11","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/gim.2013.73","volume":"15","author":"RC Green","year":"2013","unstructured":"Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15:565\u201374. \n                    https:\/\/doi.org\/10.1038\/gim.2013.73\n                    \n                  .","journal-title":"Genet Med"},{"key":"743_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1200\/JOP.2016.019836","volume":"13","author":"RT Zon","year":"2017","unstructured":"Zon RT, Edge SB, Page RD, Frame JN, Lyman GH, Omel JL, et al. American Society of Clinical Oncology criteria for high-quality clinical pathways in oncology. J Oncol Pract. 2017;13:207\u201310. \n                    https:\/\/doi.org\/10.1200\/JOP.2016.019836\n                    \n                  .","journal-title":"J Oncol Pract"},{"key":"743_CR13","doi-asserted-by":"publisher","unstructured":"Daly B, Zon RT, Page RD, Edge SB, Lyman GH, Green SR, et al. Oncology Clinical Pathways: Charting the Landscape of Pathway Providers. J Oncol Pract. 2018;14:e194\u2013200. \n                    https:\/\/doi.org\/10.1200\/JOP.17.00033\n                    \n                  .","DOI":"10.1200\/JOP.17.00033"}],"container-title":["BMC Medical Informatics and Decision Making"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-019-0743-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12911-019-0743-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-019-0743-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T19:14:35Z","timestamp":1579288475000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedinformdecismak.biomedcentral.com\/articles\/10.1186\/s12911-019-0743-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,18]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["743"],"URL":"https:\/\/doi.org\/10.1186\/s12911-019-0743-x","relation":{},"ISSN":["1472-6947"],"issn-type":[{"type":"electronic","value":"1472-6947"}],"subject":[],"published":{"date-parts":[[2019,1,18]]},"assertion":[{"value":"18 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"OmniSeq\u2019s analysis utilized deidentified data that was considered non-human subjects research under IRB-approved protocol (BDR #073166) at Roswell Park Comprehensive Cancer Center (Buffalo, NY).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Disclosures: SP, JMC, MKN, STG, APS, BB, JA, VG, HTD, MQ, YW, FLL, and CM are all employees of OmniSeq, Inc. (Buffalo, NY) and hold restricted stock in OmniSeq, Inc. GD, MLV, AE, HC, AGM, PB, SE, SA, MO, GC, KO, KK, PF, SL, BK, CM, STG, JMC, and MSE are employees of Roswell Park Comprehensive Cancer Center (Buffalo, NY). Roswell Park Comprehensive Cancer Center is the majority shareholder of OmniSeq, Inc. MSE and LG provide remunerated consulting to OmniSeq, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"14"}}